It is time for the Board to act and to change the managment team particularly the CEO,CFO and Clinical VP. We need to have Bexxar approved and they have dropped the ball. After Steve Gillis left Immunex the company soared. It would be nice to see this happen at Corixa.
My comments were directed to the regulatory failaure with Bexxar where the CEO and Clinical/Regulatory person are responsible. However, this company is so riddled with problems such as the inability of the CFO to curb excessive spending as well as the lack of a serious pipeline from their own research that other changes are in order. All Corixa development projects are from external sources, PVAC, Bexxar and Melacine, not to mention the Ribi adjuvants. The is no substance here and a new management team should be put in place immediately. The Board owes this to the shareholders.